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BACKGROUND
Inhibition of angiogenesis is currently hot topic in the search 
for an effective treatment against hepatocellular carcinoma 
(HCC). Placental growth factor (PlGF) is a VEGF analogue only 
involved in pathologic angiogenesis and its inhibition has the 
potential to restrain tumour growth, without affecting healthy 
organs. Therefore, we assessed whether administration of PlGF-
antibodies could serve as a potential therapy for HCC in mice.
METHODS
5-week-old male mice received intraperitoneal injections with 
diethylnitrosamine (35 mg/kg bodyweight, 1x/week) leading to 
HCC after 25W. At 26W mice were treated with murine PlGF-
antibodies (20 mg/kg aPlGF, 2x/week) or IgG for 5W. PlGF-
knock-out mice (PlGF-/-) received weekly ip DEN-injections 
and were compared with their WT counterparts. Tumour 
vasculature was assessed with endoglin staining. 
 
As a marker for vessel abnormality the number of cords 
without lumen, tortuous vessels and intercapillary distances 
were quantified. Arterialisation was assessed (aSMA staining) 
and the number and size of unpaired arteries (i.e. large SMA+ 
vessels not accompanied by a bile duct) determined. Stainings 
for HIF2alpha and PCNA were used to identify hypoxia and 
proliferation.
 gehoord
RESULTS
CONCLUSION
Inhibition of PlGF has a positive effect on survival in mice with HCC. aPlGF treatment decreased the 
tumour induced vascularisation and arterialisation, without effecting healthy tissue. Furthermore, 
the normalised vasculature and reduced hypoxia, decreases the proliferation of malignant cells. 
Given that VEGF-inhibitors enhance metastasis by evoking hypoxia, the normalised activity of 
aPlGF may offer a promising target to combat HCC.
▲ Treatment 
Macroscopic evaluation of livers revealed a significantly lower 
tumour burden in anti-PlGF treated mice (p < 0,05).
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Endoglin staining: PlGF-blockage partially 
normalised the abnormal blood vessel 
structure. In PlGF-blocked tumours, fewer 
capillaries were tortuous or cords, and had 
a more normal appearance.The structural 
changes in vasculature were functionally 
relevant, as PlGF-blocked HCC nodules 
expressed lower levels of HIF-2alpha. In line 
with reports that hypoxia promotes HCC 
growth, PCNA staining showed proliferation 
of HCC cells was higher in avascular clusters 
(IgG) than in vascular regions with short 
intercapillary distances (p=0,02).
aSMA staining: in healthy liver tissue, 
arteries are always accompanied by a bile 
duct. The number and lumen size of aSMA-
positive vessels not adjacent to a bile duct 
was quantified as a marker for de novo 
arterialisation. aPlGF treatment inhibits 
arterialisation of the liver.
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▲ HCC survival after therapy with aPLGF
After 5 weeks of mAb treatment, 45% of the mice receiving 
control IgG were dead, while only 23% mortality was observed 
in the aPLGF group (N=48; P<0.05)
HCC survival after therapy with αPlGF 
▲ HCC survival in PlKO mice
After 30 weeks of DEN treatment, 58% of WT mice (N=24) but 
only 5% of PlGF-/- mice (N=21) succumbed to the disease 
(P = 0,002)
HCC survival in PlKO mice
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